Investigational drug · Phase 3
Imlifidase
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Kidney Transplantation in Highly Sensitized Patients.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
17
Any phase or sponsor naming "Imlifidase"
First trial start
2021
Oct 14, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Imlifidase", any sponsor or status.
Conditions studied
As listed on its trial records.
- Kidney Transplantation in Highly Sensitized Patients
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Imlifidase" as an intervention, largest first.
- A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient GroupPivotal-lookingActive, not recruiting
Hansa Biopharma ABIndustry
NCT05937750 · 150 participants (planned) · Start Jul 3, 2023 · Primary completion Apr 30, 2030
Drug: Imlifidase administered in the 20-HMedIdeS-19 (PAES) study · For: Long Term Efficacy and Safety
Sites: Vienna, Austria; Prague, Czechia; Bois-Guillaume, France · 14 sites in all
- Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference CohortsPivotal-lookingCompleted
Hansa Biopharma ABIndustry
NCT05369975 · 113 participants · Start Apr 19, 2022 · Primary completion Apr 21, 2026
Drug: Imlifidase · For: Kidney Transplantation in Highly Sensitized Patients
Sites: Vienna, Austria; Leuven, Belgium; Prague, Czechia · 22 sites in all
- Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of KidneysActive, not recruiting
Hansa Biopharma ABIndustry
NCT05714514 · 64 participants (planned) · Start Apr 21, 2023 · Primary completion Dec 31, 2027
Drug: Imlifidase administered in the ConfIdeS study · For: Kidney Transplantation in Highly Sensitized Patients
Sites: Birmingham, Alabama; Los Angeles, California; Chicago, Illinois · 14 sites in all
- Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney TxPivotal-lookingCompleted
Hansa Biopharma ABIndustry
NCT04935177 · 64 participants · Start Oct 14, 2021 · Primary completion Jun 20, 2025
Drug: Imlifidase; IVIg and 2 more · For: Kidney Transplantation in Highly Sensitized Patients
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 25 sites in all
- A Study With Imlifidase in Anti-GBM DiseasePivotal-lookingTerminated
Hansa Biopharma ABIndustry
NCT05679401 · 50 participants · Start Dec 22, 2022 · Primary completion Jun 23, 2025
Drug: Imlifidase; Cyclophosphamide (CYC) and 1 more · For: Anti-Glomerular Basement Membrane Disease; Anti-Glomerular Basement Membrane Antibody Disease; Goodpasture Syndrome and 1 more
Sites: Los Angeles, California; Baltimore, Maryland; Boston, Massachusetts · 48 sites in all
Hansa Biopharma ABIndustry
NCT03611621 · 31 participants · Start Jun 27, 2018 · Primary completion Feb 14, 2023
Drug: Imlifidase · For: Kidney Transplant Failure and Rejection
Sites: Los Angeles, California; Baltimore, Maryland; New York, New York · 6 sites in all
Hansa Biopharma ABIndustry
NCT03897205 · 30 participants · Start Apr 30, 2019 · Primary completion May 28, 2022
Drug: Imlifidase · For: Kidney Transplant Rejection
Sites: Los Angeles, California; Boston, Massachusetts; Rochester, Minnesota · 14 sites in all
Hansa Biopharma ABIndustry
NCT03943589 · 30 participants · Start Nov 12, 2019 · Primary completion Feb 27, 2024
Drug: Imlifidase · For: Guillain-Barré Syndrome (GBS)
Sites: Le Kremlin-Bicêtre, France; Bordeaux, France; Limoges, France · 11 sites in all
- An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMRTerminated
Hansa Biopharma ABIndustry
NCT04711850 · 18 participants · Start Jan 20, 2021 · Primary completion Mar 30, 2023
Drug: Imlifidase · For: Kidney Transplant Rejection
Sites: Vienna, Austria; Bordeaux, France; Grenoble, France · 7 sites in all
Cedars-Sinai Medical CenterAcademic, hospital or other
NCT02426684 · 17 participants · Start Jun 16, 2015 · Primary completion Nov 10, 2017
Drug: IdeS® (Imlifidase) · For: Renal Disease
Sites: Los Angeles, California
Newest research
PubMed records naming it or its code names, newest first.
- Treatment standard - the highly sensitized kidney transplant candidate.
Martinez-Lacalle A, Meneghini M, Kervella D, et al. · Nephrol Dial Transplant 2026
- Future directions and challenges of drug development and non-human primate models.
Wang Z, Wu X · Life Sci 2026
- Innovative Management of Non-HLA Antibody and NK Cell-Mediated Rejection After Kidney Transplantation With Imlifidase: A Case Report.
Von Tokarski F, Rabant M, Goutaudier V, et al. · Am J Kidney Dis 2026
- Trends in nephrology: from nihilism to targeted treatment of antibody-mediated rejection.
Pickl JF, Oberbauer R · Nephrol Dial Transplant 2026
- Advances in HLA desensitization for kidney transplant candidates.
Chandran S, Huang E, Vo A, et al. · Curr Opin Nephrol Hypertens 2026
- One-year outcomes following imlifidase-enabled kidney transplantation in highly sensitized recipients: First Belgian experience.
Schmitt J, Bonvoisin C, Bouquegneau A, et al. · Hum Immunol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.